Aceto Corporation
#8579
Rank
$116.19M
Marketcap
United States
Country
Dr. Aya Jakobovits Ph.D. (Founder & Independent Director)
Mr. Brian Nicholas Harvey (Chief Financial Officer)
Summary
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Key Team
Dr. Francesco Galimi M.D., Ph.D. (Chief Medical Officer & Sr. VP)
Dr. Donald Healey (Chief Technology Officer)
Dr. Blake Aftab Ph.D. (Sr. VP & Chief Scientific Officer)
Dr. Nancy L. Boman M.D., Ph.D. (Sr. VP & Chief Regulatory Officer)
References
Dr. Aya Jakobovits Ph.D. (Founder & Independent Director)
Mr. Brian Nicholas Harvey (Chief Financial Officer)